SPRO

Spero Therapeutics Stock Price

16.45
-0.18 (-1.08%)
Upgrade to Real-Time
Afterhours (Closed)
16.45
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Spero Therapeutics Inc SPRO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.18 -1.08% 16.45 00:00:10
Open Price Low Price High Price Close Price Prev Close
16.57 16.17 17.00 16.45 16.63
Bid Price Ask Price Spread News
14.91 21.50 6.59 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,436 239,375 $ 16.61 $ 3,976,264 389,729 5.25 - 23.639
Last Trade Time Type Quantity Stock Price Currency
18:05:57 10 $ 16.91 USD

Spero Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 447.39M 27.20M 24.63M $ 18.15M $ - -3.32 -3.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Spero Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SPRO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week17.5017.5715.8216.43231,761-1.05-6.0%
1 Month18.7523.63915.8218.70442,387-2.30-12.27%
3 Months14.1823.63912.7317.11313,6412.2716.01%
6 Months13.7423.6398.5013.98320,2122.7119.72%
1 Year9.0323.6395.2513.03231,3117.4282.17%
3 Years12.3023.6395.2512.31125,0944.1533.74%
5 Years13.2523.6395.2512.28124,7473.2024.15%

Spero Therapeutics Description

Spero Therapeutics Inc is a US-based clinical-stage biopharmaceutical company. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections. The company's product candidate, SPR994, is designed as a broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It has developed platform technology known as Potentiator Platform to develop drugs to expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. In addition, the company is developing SPR720, an oral antibiotic designed for the treatment of pulmonary non-tuberculous mycobacterial infections. The pipeline products include SPR741, SPR206, and SPR720.


Your Recent History
NASDAQ
SPRO
Spero Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.